Ceftobiprole: drug evaluation and place in therapy

References

• Davies TA, Page MG, Shang W, et al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2007;51(7):2621–2624.
   PubMed Web of Science ®Google Scholar
• Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2001;45(3):825–836.
   PubMed Web of Science ®Google Scholar
• Lovering AL, Gretes MC, Safadi SS, et al. Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole. J Biol Chem. 2012;287(38):32096–32102.
   PubMed Web of Science ®Google Scholar
• Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana. [cited 2019 Apr 26]. Available from: https://globenewswire.com/news-release/2018/03/06/1415442/0/en/Basilea-reports-launch-of-antibiotic-Zevtera-ceftobiprole-in-Argentina-by-Grupo-Biotoscana.html
   Google Scholar
• CISION. News. Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel. [ cited 2019 Apr 26]. Available from: https://www.newswire.ca/news-releases/cardiome-announces-agreement-with-basilea-fordistribution-of-zevteramabelio-ceftobiprole-in-europe-and-israel-643915603.html
   Google Scholar
• Falco V, Burgos J, Almirante B. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018;19(13):1503–1509.
   PubMed Web of Science ®Google Scholar
• Queenan AM, Shang W, Kania M, et al. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother. 2007;51(9):3089–3095.
   PubMed Web of Science ®Google Scholar
• Ednie L, Shapiro S, Appelbaum PC. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diagn Microbiol Infect Dis. 2007;58(1):133–136.
   PubMed Web of Science ®Google Scholar
• Jones RN, Deshpande LM, Mutnick AH, et al. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother. 2002;50(6):915–932.
   PubMed Web of Science ®Google Scholar
• Zbinden R, Punter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrob Agents Chemother. 2002;46(3):871–874.
   PubMed Web of Science ®Google Scholar
• Bal AM, David MZ, Garau J, et al. Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: an in-depth review of newer antibiotics active against an enduring pathogen. J Glob Antimicrob Resist. 2017;10:295–303.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Flamm RK, Sader HS, et al. Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. Antimicrob Agents Chemother. 2014;58(7):3882–3888.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Flamm RK, Duncan LR, et al. Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). Diagn Microbiol Infect Dis. 2018;91(1):77–84.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Flamm RK, Mendes RE, et al. Ceftobiprole activity against Gram-positive and -negative pathogens collected from the United States in 2006 and 2016. Antimicrob Agents Chemother. 2019;63:1.
   Web of Science ®Google Scholar
• Rossolini GM, Dryden MS, Kozlov RS, et al. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J Antimicrob Chemother. 2011;66(1):151–159.
   PubMed Web of Science ®Google Scholar
• Santerre Henriksen A, Smart JI, Hamed K. Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015. Infect Drug Resist. 2018;11:1309–1320.
   PubMed Web of Science ®Google Scholar
• Pillar CM, Aranza MK, Shah D, et al. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother. 2008;61(3):595–602.
   PubMed Web of Science ®Google Scholar
• Walkty A, Adam HJ, Laverdiere M, et al. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011;69(3):348–355.
   PubMed Web of Science ®Google Scholar
• Barber KE, Werth BJ, Ireland CE, et al. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother. 2014;69(11):3006–3010.
   PubMed Web of Science ®Google Scholar
• Campanile F, Bongiorno D, Mongelli G, et al. Bactericidal activity of ceftobiprole combined with different antibiotics against selected Gram-positive isolates. Diagn Microbiol Infect Dis. 2019;93(1):77–81.
   PubMed Web of Science ®Google Scholar
• Kresken M, Korber-Irrgang B, Lauffer J, et al. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology. Int J Antimicrob Agents. 2011;38(1):70–75.
   PubMed Web of Science ®Google Scholar
• Abbanat D, Shang W, Amsler K, et al. Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays. Int J Antimicrob Agents. 2014;43(1):32–39.
   PubMed Web of Science ®Google Scholar
• Hischebeth GTR, Gravius S, Molitor E, et al. Activity of ceftobiprole against Staphylococcus spec. isolates derived from foreign body associated infections. Diagn Microbiol Infect Dis. 2018;91(2):175–178.
   PubMed Web of Science ®Google Scholar
• Isnard C, Dhalluin A, Malandain D, et al. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections. J Glob Antimicrob Resist. 2018;13:221–225.
   PubMed Web of Science ®Google Scholar
• Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet. 2008;47(1):21–33.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004;48(7):2570–2575.
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008;52(10):3492–3496.
   PubMed Web of Science ®Google Scholar
• Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob Agents Chemother. 2008;52(7):2389–2394.
   PubMed Web of Science ®Google Scholar
• Torres A, Mouton JW, Pea F. Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations. Clin Pharmacokinet. 2016;55(12):1507–1520.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Nicolau DP, Lodise TP, et al. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother. 2009;53(8):3294–3301.
   PubMed Web of Science ®Google Scholar
• Barbour A, Schmidt S, Sabarinath SN, et al. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother. 2009;53(7):2773–2776.
   PubMed Web of Science ®Google Scholar
• Syed YY. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia. Drugs. 2014;74(13):1523–1542.
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Merelli M, De Stefanis P, et al. Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient. Eur J Clin Pharmacol. 2018;74(12):1671–1672.
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Mouton JW. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Antimicrob Agents Chemother. 2014;58(5):2512–2519.
   PubMed Web of Science ®Google Scholar
• Muller AE, Schmitt-Hoffmann AH, Punt N, et al. Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study. Antimicrob Agents Chemother. 2013;57(5):2047–2053.
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Engelhardt M, et al. Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects. Clin Pharmacol Drug Dev. 2018;7(7):781–787.
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59(1):51–61.
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Welte T, File TM Jr., et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39(3):240–246.
   PubMed Web of Science ®Google Scholar
• Vaudaux P, Gjinovci A, Bento M, et al. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49(9):3789–3793.
   Web of Science ®Google Scholar
• Scheeren TWL, Welte T, Saulay M, et al. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials. BMC Infect Dis. 2019;19(1):195.
   PubMedGoogle Scholar
• Bassetti M, Righi E, Vena A, et al. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018;24(5):385–393.
   PubMed Web of Science ®Google Scholar
• Chaubey V, Dalton B, Sabuda D, et al. Abstract SP26: Ceftobiprole use in methicillin resistant Staphylococcus aureus (MRSA) bacteremia and pneumonia. CACMID-AMMI Canada 2010).
   Google Scholar
• Esposito F, Efthymiou A, Van Delden C, et al. Ceftobiprole as an ultimate successful therapy for MRSE prosthetic endovascular infection judged to be medically untreatable in a profound immunocompromised patient: a case report. Joint annual meeting 2018. Swiss Societies for Infectious Diseases (SSI), Hospital Hygiene (SSHH), Tropical Medicine and Parasitology (SSTMP) and Tropical and Travel Medicine (SSTTM); September 13-14, 2018; Interlaken, Switzerland. Poster P88.
   Google Scholar
• Macdonald A, Dow G. Ceftobiprole: first reported experience in osteomyelitis. Can J Infect Dis Med Microbiol. 2010;21(3):138–140.
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46(5):647–655.
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52(1):37–44.
   PubMed Web of Science ®Google Scholar
• Oltolini C, Castiglioni B, Tassan Din C, et al. Meticillin-resistant Staphylococcus aureus endocarditis: first report of daptomycin plus ceftobiprole combination as salvage therapy. Int J Antimicrob Agents. 2016;47(6):502–504.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, 2010 [cited 2019 Apr 26]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-recommendation-refusal-marketing-authorisation-zeftera_en-0.pdf
   Google Scholar
• Entenza JM, Veloso TR, Vouillamoz J, et al. In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(9):3977–3984.
   PubMed Web of Science ®Google Scholar
• Tattevin P, Basuino L, Bauer D, et al. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(2):610–613.
   PubMed Web of Science ®Google Scholar
• Barnea Y, Navon-Venezia S, Kuzmenko B, et al. Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model. Eur J Clin Microbiol Infect Dis. 2014;33(3):325–329.
   PubMed Web of Science ®Google Scholar
• Rello J, Rahav G, Scheeran T, et al. A pooled analysis of clinical cure and mortality with ceftobiprole medocaril versus comparators in staphylococcal bacteraemia in complicated skin infections, and community- and hospital-acquired pneumonia. ECCMID 2016: O-318).
   Google Scholar
• Werth BJ, Barber KE, Tran KN, et al. Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. J Antimicrob Chemother. 2015;70(2):489–493.
   PubMed Web of Science ®Google Scholar
• Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis. 2007;58(3):363–365.
   PubMed Web of Science ®Google Scholar
• Saleh-Mghir A, Dumitrescu O, Dinh A, et al. Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother. 2012;56(12):6291–6297.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004;48(7):2576–2580.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Refusal assessment report for Zeftera (previously known as Zevtera). European Medicines Agency; 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Public_assessment_report/human/000883/WC500096883.pdf
   Google Scholar
• Basilea Medical Ltd. Public assessment report, Zevtera 500mg powder for concentrate for solution for infusion. Medicines and Healthcare Products Regulatory Agency.
   Google Scholar
• Nerandzic MM, Donskey CJ. Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice. Antimicrob Agents Chemother. 2011;55(5):2174–2177.
   PubMed Web of Science ®Google Scholar
• Backstrom T, Panagiotidis G, Beck O, et al. Effect of ceftobiprole on the normal human intestinal microflora. Int J Antimicrob Agents. 2010;36(6):537–541.
   PubMed Web of Science ®Google Scholar
• Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12(6):894–899.
   PubMed Web of Science ®Google Scholar
• Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48(8):2871–2875.
   PubMed Web of Science ®Google Scholar
• Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53(2):158–163.
   PubMed Web of Science ®Google Scholar
• Mehta S, Singh C, Plata KB, et al. beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56(12):6192–6200.
   PubMed Web of Science ®Google Scholar
• Werth BJ, Barber KE, Kieu-Nhi TT, et al. Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. J Antimicrob Chemother. 2015;70(2):489–493.
   PubMed Web of Science ®Google Scholar